180 Life Sciences

180 Life Sciences Corp. is a clinical-stage biotechnology company based in Palo Alto, California. With a team of four employees, the company has generated $2.5 million in revenue. 180 Life Sciences Corp. is publicly traded on the NASDAQ stock exchange under the ticker symbol ATNF. 180 Life Sciences focuses on developing novel drugs to address unmet medical needs in inflammatory diseases, fibrosis, and pain. Their research targets inflammation, a key driver of various diseases, aiming to develop effective therapies for conditions lacking satisfactory treatment options. Their primary platform centers on a novel program using anti-TNF (tumor necrosis factor) to treat fibrosis. The company draws on the expertise of leading researchers from Oxford University, the Hebrew University, and Stanford University, fostering innovation in their drug development efforts. For more information about 180 Life Sciences Corp. and their research, please visit their website at 180lifesciences.com.